Happy with the progress. $136M MSV! Slightly down from the busiest quarter (Dec 2022 $141M) of the year. Up 34% YOY. Expenses down $5M. 15% down. Things are looking up. RBR
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%